Anika Therapeutics (NASDAQ:ANIK – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Barrington Research in a note issued to investors on Tuesday, Benzinga reports. They presently have a $37.00 price objective on the biotechnology company’s stock. Barrington Research’s price objective would indicate a potential upside of 50.77% from the company’s previous close.
Anika Therapeutics Stock Down 0.6 %
NASDAQ:ANIK opened at $24.54 on Tuesday. Anika Therapeutics has a 52 week low of $18.08 and a 52 week high of $29.11. The stock’s fifty day moving average is $25.09 and its two-hundred day moving average is $25.79. The company has a market capitalization of $357.96 million, a P/E ratio of -4.67 and a beta of 0.83.
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.24). The company had revenue of $41.92 million during the quarter, compared to analysts’ expectations of $39.90 million. Anika Therapeutics had a negative net margin of 44.45% and a positive return on equity of 0.94%. During the same quarter last year, the firm posted ($0.06) earnings per share. Sell-side analysts anticipate that Anika Therapeutics will post -0.1 earnings per share for the current fiscal year.
Institutional Trading of Anika Therapeutics
About Anika Therapeutics
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
Featured Articles
- Five stocks we like better than Anika Therapeutics
- What is the Shanghai Stock Exchange Composite Index?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- 3 Warren Buffett Stocks to Buy Now
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.